Premium
Lithium augmentation in sertraline‐resistant depression: a preliminary dose‐response study
Author(s) -
Dinan T. G.
Publication year - 1993
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1993.tb03461.x
Subject(s) - sertraline , lithium carbonate , lithium (medication) , depression (economics) , medicine , anesthesia , antidepressant , chemistry , ion , macroeconomics , organic chemistry , hippocampus , ionic bonding , economics
Eleven patients with DSM‐III‐R major depression who were treatment‐resistant to sertraline were allocated for lithium augmentation therapy. In conjunction with their sertraline, 6 received lithium carbonate 400 mg at night and 5 received 800 mg at night. A total of 7 patients responded within 1 week. The degree of response was not related to the serum lithium level. Patients with lithium levels as low as 0.3 mEq/l responded. No significant side effects were reported.